image: From front left - CFO Lorna Collings, Investment Director Dr Sohaib Mir, Investment Director Dr Robert Balfour, CIO Dr Graeme Martin, Analyst Katie Sunnucks and CEO Alek Safarian (not pictured Investment Manager Julia Jones) view more
Credit: ALSA Ventures
London, UK - ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development.
ALSA Ventures CEO Alek Safarian said:
"Our model is to work very closely with management teams we invest in. We have considerable bench strength in clinical development experience within the ALSA team, so launching this Accelerator makes a lot of sense on a number of levels."
Under the Eclipse framework, eligible companies will be selected for equity investment and funding through ALSA's inaugural fund, ALSA Ventures I SCSp. Applications will be assessed on a competitive basis quarterly, with equity investment of up to $5M offered to awarded companies. Upon receipt of this investment, awarded companies will work with global clinical research organisation ICON to progress their asset through first-in-man studies.
"We are very pleased to have ICON, a leading global provider of outsourced clinical services, support the Eclipse initiative with capabilities across the full spectrum of consulting and clinical development services," said Safarian.
The Eclipse development programme will invest in novel therapeutic drugs that aim to solve high unmet need, and will focus on scientific innovation in the UK and Europe.
To learn more about the application process and how the Eclipse model works visit: https://www.alsaventures.com/eclipse/summary
###
About ALSA Ventures http://www.alsaventures.com
ALSA Ventures is a UK and EU biotechnology investment firm with a focus on novel therapeutics at preclinical POC or early clinical development stage. The firm was established in 2019, by Alek Safarian, founder and ex-CEO of clinical CRO, Novotech. ALSA Ventures recently announced the first closing of its European biotechnology investment fund, and has made three investments to date.
Media contact:
Susan Fitzpatrick-Napier
Team@DMGPR.Com